Mitsubishi UFJ Trust & Banking Corp Cuts Stake in Biogen Inc. $BIIB

Key Points

• Mitsubishi UFJ Trust & Banking Corp cut its stake in Biogen by 22.8% in Q4, leaving it with 65,318 shares valued at about $11.495 million.
• Biogen reported a Q1 beat—EPS $3.57 vs. $2.95 expected and revenue $2.48B vs. $2.29B—set FY2026 guidance of 14.25–15.25 EPS, and has an average analyst target of $214.23 amid mixed buy/hold ratings.
• Insider Priya Singhal sold 2,660 shares (a 24.85% reduction), while company insiders own just 0.18% and institutional investors hold 87.93% of Biogen's shares.

Mitsubishi UFJ Trust & Banking Corp lowered its position in Biogen Inc. (NASDAQ:BIIB - Free Report) by 22.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 65,318 shares of the biotechnology company's stock after selling 19,342 shares during the quarter. Mitsubishi UFJ Trust & Banking Corp's holdings in Biogen were worth $11,495,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also bought and sold shares of BIIB. WPG Advisers LLC boosted its holdings in Biogen by 417.9% during the 4th quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company's stock valued at $26,000 after acquiring an additional 117 shares during the period. Accredited Wealth Management LLC boosted its holdings in Biogen by 1,233.3% during the 3rd quarter. Accredited Wealth Management LLC now owns 200 shares of the biotechnology company's stock valued at $28,000 after acquiring an additional 185 shares during the period. First Horizon Corp purchased a new stake in Biogen during the 4th quarter valued at about $30,000. WFA of San Diego LLC purchased a new stake in Biogen during the 2nd quarter valued at about $32,000. Finally, True Wealth Design LLC boosted its holdings in Biogen by 62.9% during the 3rd quarter. True Wealth Design LLC now owns 233 shares of the biotechnology company's stock valued at $33,000 after acquiring an additional 90 shares during the period. Hedge funds and other institutional investors own 87.93% of the company's stock.

Insiders Place Their Bets

In related news, insider Priya Singhal sold 2,660 shares of the firm's stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $199.83, for a total transaction of $531,547.80. Following the completion of the transaction, the insider owned 8,043 shares of the company's stock, valued at $1,607,232.69. This trade represents a 24.85% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.18% of the stock is currently owned by company insiders.

Biogen Stock Down 1.2%

BIIB stock opened at $187.06 on Friday. Biogen Inc. has a twelve month low of $115.25 and a twelve month high of $202.41. The company has a quick ratio of 2.03, a current ratio of 3.06 and a debt-to-equity ratio of 0.34. The firm has a market cap of $27.45 billion, a PE ratio of 20.07, a price-to-earnings-growth ratio of 1.55 and a beta of 0.16. The business has a 50 day moving average of $184.52 and a 200 day moving average of $176.06.

Biogen (NASDAQ:BIIB - Get Free Report) last posted its quarterly earnings data on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share for the quarter, beating analysts' consensus estimates of $2.95 by $0.62. Biogen had a return on equity of 12.83% and a net margin of 13.81%.The company had revenue of $2.48 billion during the quarter, compared to analyst estimates of $2.29 billion. During the same quarter last year, the company earned $3.02 EPS. The firm's revenue for the quarter was up 1.9% on a year-over-year basis. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. On average, research analysts forecast that Biogen Inc. will post 15.26 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on BIIB. Wolfe Research set a $231.00 target price on Biogen in a report on Monday, February 9th. Piper Sandler upgraded Biogen from a "neutral" rating to an "overweight" rating and increased their target price for the company from $177.00 to $214.00 in a report on Tuesday, April 14th. HC Wainwright increased their target price on Biogen from $228.00 to $237.00 and gave the company a "buy" rating in a report on Thursday, April 2nd. JPMorgan Chase & Co. increased their target price on Biogen from $175.00 to $185.00 and gave the company a "neutral" rating in a report on Thursday, April 23rd. Finally, Rothschild & Co Redburn increased their target price on Biogen from $180.00 to $190.00 in a report on Thursday. Thirteen research analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Biogen has an average rating of "Hold" and an average target price of $214.23.

Trending Headlines about Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Q1 beat driven by growth from newer drugs (Leqembi, Skyclarys) and upbeat revenue/profit metrics that underpin optimism about Biogen’s growth portfolio. Bristol Myers’ legacy lift, Biogen’s blue skies and Regeneron’s murky outlook
• Positive Sentiment: RBC raised its price target to $222 and maintained an Outperform rating, signaling strong analyst conviction and upside potential for BIIB. RBC raises PT to $222
• Positive Sentiment: H.C. Wainwright reiterated a Buy and lifted its PT to $237, citing reduced risk on BIIB080 (Alzheimer’s) — a bullish signal for upside from pipeline progress. H.C. Wainwright reiterates Buy, PT $237
• Positive Sentiment: TD Cowen initiated / affirmed a Buy with a $215 price target, citing strong Q1, pipeline progress and the Apellis deal as supportive factors. TD Cowen Buy, PT $215
• Positive Sentiment: Rothschild & Co Redburn nudged its PT up to $190 (small upside), reflecting modestly improved near-term views. Rothschild raises PT to $190
• Neutral Sentiment: BMO kept a Market Perform/Hold rating with an unchanged $196 target, signaling that some analysts see constrained near-term growth despite the beat. BMO maintains Hold, PT $196
• Neutral Sentiment: Several analyst notes and commentary highlight mixed takeaways: firms generally raised forecasts after the Q1 beat but some also trimmed FY2026 EPS expectations, producing varied buy/hold calls. Analysts boost forecasts after Q1
• Negative Sentiment: Biogen disclosed the Apellis transaction will create a ~$120M–$130M other‑income headwind in 2026 (non‑GAAP EPS accretion expected in 2027), creating a near‑term earnings drag that pressured sentiment. Apellis deal impact
• Negative Sentiment: Sanford C. Bernstein trimmed its PT slightly from $201 to $200 — a modest negative signal that may contribute to profit-taking amid mixed analyst reactions. Bernstein trims PT to $200

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer's disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company's marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.